NDAINJECTIONINJECTABLE
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOGRAFIN-76 is a high-osmolality ionic contrast medium containing diatrizoate meglumine used for diagnostic radiographic imaging procedures. It is administered via injection to visualize internal structures during medical imaging studies. This product enables visualization of vascular, urinary, and other organ systems during diagnostic procedures.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), signaling potential team restructuring and transition planning activity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RENOGRAFIN-76 currently shows zero linked job openings, reflecting its mature, stable market position with limited growth. Career opportunities on this product are primarily in product stewardship, compliance, and legacy brand management rather than high-growth commercial expansion.
Brand ManagerProduct Manager
Worked on RENOGRAFIN-76 at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.